Cancer Clinical Trial
Official title:
Time of Treatment With Low Molecular Weight Heparins in Cancer Patients With Thromboembolic Disease. Procoagulant Role of Phospholipid-dependent Microparticles.
Verified date | April 2017 |
Source | Delos Clinical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all
episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer
related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH)
during at least 3 months, but nowadays the duration of treatment is not accurately
determined.
The D-Dimer determination has been used like recurrence predictors after LMWH treatment
suspension, but in cancer patients the useful is limited. Phospholipid-dependent
microparticles could been used like recurrence predictors in cancer patients and tailored
the duration of LMWH treatment for each patient.
Status | Completed |
Enrollment | 352 |
Est. completion date | March 31, 2017 |
Est. primary completion date | December 31, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient with diagnosis of cancer (any) and diagnosis of pulmonary thromboembolism (PT) or venous thromboembolism (VT) , in treatment with low molecular weight heparin (LMWH). - Patients treated with LMWH since cancer diagnostic. - Signed informed consent sheet Exclusion Criteria: - Patients with life expectancy lower than 6 months - Pregnancy woman - Patients with cerebral metastasis |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Delos Clinical |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence thromboembolisms | Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression | 3 months | |
Primary | Recurrence thromboembolisms | Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression | 6 months | |
Secondary | Hemorrhagic events | Hemorrhagic events due to LMWH treatment | 6 months | |
Secondary | Thromboembolic event attributable death | Death related to embolic event | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|